Pacira BioSciences (PCRX) Stock Price, News & Analysis

Company Overview

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Key Stats

• Today's Range: $16.21 to $16.66
• 50-Day Range: $12.73 to $17.70
• 52-Week Range: $11.16 to $35.95
• Volume: 780,465 shs
• Average Volume: 535,337 shs
• Market Capitalization: $766.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.50
• Consensus Rating: Hold

Pacira BioSciences Stock Analysis - MarketRank™

Pacira BioSciences scored higher than 78% of companies evaluated by MarketBeat, and ranked 230th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 4 buy ratings, 4 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Pacira BioSciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -4.42%

Earnings Growth

Earnings for Pacira BioSciences are expected to decrease by -4.42% in the coming year, from $2.26 to $2.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pacira BioSciences is -8.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pacira BioSciences is -8.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pacira BioSciences has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.83% of the outstanding shares of Pacira BioSciences have been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Pacira BioSciences has recently decreased by 11.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pacira BioSciences does not currently pay a dividend.

Dividend Growth

Pacira BioSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.89

Percentage of Shares Shorted

11.83% of the outstanding shares of Pacira BioSciences have been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Pacira BioSciences has recently decreased by 11.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.57

News Sentiment

Pacira BioSciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Pacira BioSciences this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 1 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,430.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Pacira BioSciences is held by insiders.

Percentage Held by Institutions

99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PCRX Stock Analysis - Frequently Asked Questions

How have PCRX shares performed this year?

Pacira BioSciences' stock was trading at $33.74 at the start of the year. Since then, PCRX shares have decreased by 50.8% and is now trading at $16.60.
View the best growth stocks for 2024 here.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.72 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.07. The company's revenue was up 8.7% compared to the same quarter last year.

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' top institutional investors include Pacer Advisors Inc. (10.75%), State Street Corp (4.36%), Geode Capital Management LLC (2.35%) and Assenagon Asset Management S.A. (1.20%). Insiders that own company stock include David M Stack, Daryl Gaugler, Kristen Williams, Jonathan Slonin, Roy Winston, Lauren Riker, Charles A Reinhart III, Max Reinhardt, Charles Anthony Laranjeira, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson, Marcelo Bigal and John P Phd Longenecker.
View institutional ownership trends.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PCRX
• CUSIP: 69512710
• CIK: 1396814
• Web: www.pacira.com
• Phone: (813) 553-6680
• Fax: 302-655-5049
• Employees: 720
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.50
• High Stock Price Target: $57.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +41.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 7.55
• P/E Growth: N/A
• Net Income: $41.96 million
• Net Margins: -13.07%
• Pretax Margin: -7.91%
• Return on Equity: 13.42%
• Return on Assets: 7.19%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 2.25
• Quick Ratio: 1.89

Sales & Book Value

• Annual Sales: $674.98 million
• Price / Sales: 1.14
• Cash Flow: $3.99 per share
• Price / Cash Flow: 4.16
• Book Value: $16.23 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 46,170,000
• Free Float: 43,218,000
• Market Cap: $766.42 million
• Optionable: Optionable
• Beta: 0.82